share_log

HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $11

Benzinga ·  Jan 17 19:25

HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and raises the price target from $10 to $11.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment